Written by: Kayla Randle, PharmD, BCPS, BCOP, Kaiser Permanente Georgia Oncology
Download Here 

The purpose of this PQI is to identify differentiating characteristics which would indicate zanubrutinib (Brukinsa) as a preferred treatment option in Mantle Cell Lymphoma as well as discussing key counseling and monitoring criteria to improve patient outcomes.
Continue reading Zanubrutinib Patient Selection and Management in Mantle Cell Lymphoma

Read More

Written by: Kirollos Hanna, PharmD, BCPS, BCOP, University of Minnesota Medical Center & Mayo Clinic
Download Here

Ixazomib (Ninlaro) is the only oral proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy. This PQI highlights the management, safety, and efficacy of ixazomib.
Continue reading Ixazomib in the Treatment of Multiple Myeloma

Read More

Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health
Download Here

Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion and exon 21 L858R.This PQI aims to provide guidance for initiating therapy with osimertinib. Continue reading Osimertinib (Tagrisso) in EGFR Positive NSCLC

Read More